IRAK4: Is a New "Top Target" for Targeted Drugs Emerging?

Author: Senior Product Manager of UA Views：858

In the immune system's intricate network, abnormal activation of signaling pathways is central to various inflammatory diseases and tumorigenesis. IL-1 receptor-associated kinase 4 (IRAK4), a key node in the TLR/IL-1R signaling pathway, has dual functions (kinase activity and scaffolding function), making it a core target for regulating innate and adaptive immunity. Recent advances in IRAK4-targeted drug development offer new strategies for treating autoimmune diseases and cancers.

Recent Advances
Product Information
Reference

Recent Advances

IRAK4

Introduction

Biological Functions and Signaling Pathways of IRAK4

Part of the serine/threonine kinase family, IRAK4 activates downstream NF-κB and MAPK pathways via its N-terminal death domain (DD) by binding to MyD88 to form the Myddosome complex. Its unique features are as follows: Kinase activity: It phosphorylates IRAK1 and TAK1, promoting the nuclear translocation of NF-κB and AP-1 transcription factors and the release of pro-inflammatory factors like TNF-α and IL-6. Scaffolding function: Independent of kinase activity, it stabilizes the Myddosome complex structure, ensuring sustained signaling.

Studies show that IRAK4 overexpression enhances LPS-induced NADPH oxidase activity and activates the p38 MAPK pathway, expanding its regulatory network. This dual mechanism makes it an "irreplaceable node" in the TLR/IL-1R signaling pathway.

IRAK4 and Diseases

Autoimmune Diseases

Rheumatoid arthritis (RA): IRAK4 deficiency significantly reduces NF-κB-induced inflammatory responses and synovial inflammation in RA. Systemic lupus erythematosus (SLE): Excessive IRAK4 activation causes TLR7/9 signaling disorders, leading to autoantibody and immune complex deposition. Atopic dermatitis (AD): IRAK4 plays a key role in Th2-type inflammation, and inhibiting it reduces the secretion of IL-4 and IL-13.

Tumor Progression

Hematologic malignancies: In acute myeloid leukemia (AML), IRAK4-L overexpression is linked to poor prognosis. In DLBCL, MyD88-L265P mutations rely on IRAK4 to activate the NF-κB pathway. Solid tumors: In pancreatic cancer, the IL-1β-IRAK4 feedback loop drives tumor fibrosis and chemotherapy resistance. In colorectal cancer, IRAK4 mediates inflammation-induced tumorigenesis.

Respiratory Diseases

IRAK4 is a potential target for treating exacerbated airway diseases. Inflammatory lung diseases like asthma and COPD are significant health burdens with treatment limitations. As a key signaling hub downstream of IL-1 receptors and TLRs, IRAK4 is involved in multiple inflammatory pathways. Studies show IRAK4 regulates LPS- or cigarette smoke-induced pulmonary inflammation in mouse models, and the novel IRAK4 inhibitor BI1543673 shows inhibitory effects on TLR-induced inflammation in human lung tissue.

IRAK4 Targeted Drug Development

Small Molecule Inhibitors

Mechanism: Competitively bind to IRAK4's ATP-binding pocket to inhibit kinase activity. Challenges: Traditional inhibitors cannot block scaffolding functions, limiting efficacy.

PROTAC Degraders

Advantages: Selectively degrade IRAK4 via the ubiquitin-proteasome system (UPS), blocking both kinase and scaffolding functions.

Representative Drugs

KT-474 (Kymera/Sanofi): The fastest global IRAK4 PROTAC in development, in Phase II trials for AD and HS, with Phase I trials showing significant reduction in IL-6 and TNF-α levels. BGB-45035 (BeiGene): Developed on the CDAC platform, Phase I studies show superior degradation depth and speed compared to similar drugs.

Multi-Target Inhibitors Strategy

Jointly inhibit IRAK4 and other kinases (e.g., BTK, IRAK1) to enhance efficacy. For instance, ARD-885 from Alauda Therapeutics, an IRAK1/4 dual-target inhibitor, has been approved for RA clinical trials.

Conclusion

As a core immunoregulatory target, IRAK4's dual functions and broad disease associations make it a hot spot for drug development. Despite challenges, PROTAC technology breakthroughs and multi-target inhibitor development offer new hope for IRAK4-targeted therapy. In the future, with deepening mechanism research and accumulating clinical evidence, IRAK4 is expected to become a key target for treating inflammatory diseases and cancers, bringing more precise and effective treatment options for patients.

Related Product Recommendations:

Target Protein
Catalog Number	Product Name
UA080294	IRAK4 His Tag Protein, Human
UA080103	IRAK4 GST Tag Protein, Huamn
UA080454	IRAK4 Protein, Human
E3 Ubiquitin Ligases
Catalog Number	Product Name
UA080262	Biotinylated CRBN/DDB1 Protein
UA080011	DDB1/CRBN Complex, His Tag Protein
UA080275	Cullin4A-RBX1-DDB1-CRBN Protein
UA080012	VHL/Elongin-C/Elongin-B Complex, His Tag Protein
UA080274	Cullin2-RBX1-ElonginB/C-VHL Protein

活性数据分享：

IRAK4 GST Tag Protein, Human 货号： UA080103

IKAK4 titration in ADP-Glo assay

The IKAK4 activity was detected using Ultra Luminescence technology. The reaction was performed by incubating the IRAK4 protein, ATP and substrate at 25℃ for 60 min, then adding ADP-Glo reagent and reading RLU with BMG.

Xiaoxia Li. IRAK4 in TLR/IL-1R signaling: Possible clinicalapplications. European Journal of Immunology.2008.
Guillermo Garcia‐Manero; Uwe Platzbecker; Kian‐Huat Lim; Grzegorz S. Nowakowski; Omar Abdel‐Wahab; et al. Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer. Frontiers in Hematology.2024.
Ulrich Bothe; Judith Günther; Reinhard Nubbemeyer; Hölger Siebeneicher; Sven Ring; et al. Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839. Journal of Medicinal Chemistry.2024.
Joseph A. Jude; Reynold A. Panettieri. IRAK4: potential therapeutic target for airway disease exacerbations. Trends in Pharmacological Sciences.2025.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

Reference

Xiaoxia Li. IRAK4 in TLR/IL-1R signaling: Possible clinicalapplications. European Journal of Immunology.2008.
Guillermo Garcia‐Manero; Uwe Platzbecker; Kian‐Huat Lim; Grzegorz S. Nowakowski; Omar Abdel‐Wahab; et al. Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer. Frontiers in Hematology.2024.
Ulrich Bothe; Judith Günther; Reinhard Nubbemeyer; Hölger Siebeneicher; Sven Ring; et al. Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839. Journal of Medicinal Chemistry.2024.
Joseph A. Jude; Reynold A. Panettieri. IRAK4: potential therapeutic target for airway disease exacerbations. Trends in Pharmacological Sciences.2025.

The Last The Next